To overview |
|
| | |||
| Personal Change |
| Carl Zeiss Meditec intends to speed up growth and restructures management board | Downloads and Links | ||
| Michael Kaschke appointed new CEO – Development in third quarter 2007/2008 restrained as expected | RTF Documents
english (494 KB)Further Information 
Deutsche Version
| ||
| JENA/Germany, 22.07.2008. The medical technology company Carl Zeiss Meditec AG, listed in the TecDAX at the German Stock Exchange (ISIN DE0005313704), intends to speed up growth. Therefore, at its meeting on June 21st, 2008, the Supervisory Board has agreed on a new structure for the Management Board. Effective from June 22nd, 2008, Michael Kaschke (51), has been appointed Chief Executive Officer of Carl Zeiss Meditec AG. Until further notice, Kaschke’s appointment as chairman of the supervisory board is suspended. Markus Guthoff accepts office as chairman of the Supervisory Board. In order to advance the performance in international growth markets, Ulrich Krauss (44) will focus his attention in the board exclusively on worldwide sales and distribution. Bernd Hirsch (37) und Ludwin Monz (44) will continue their appointment to the management board. For personal reasons, James L. Taylor (59) has notified the company of his intent to resign from his duties as a Member of the Management Board effective immediately. He will focus on the strategic business unit Ophthalmic Systems primarily in the strategically important US market. In the first nine months of the financial year 2007/2008, Carl Zeiss Meditec achieved a consolidated revenue of about EUR 445 million and an EBIT of about EUR 50 million. “Key figures of the last months in general confirm the forecast for fiscal year 2007/08, but do not point to a sustainable trend for the accelerated growth we envisioned for our company in the promising market for medical technology”, says Michael Kaschke. “The whole Management Board is convinced that the Carl Zeiss Meditec has significant untapped potentials for growth and that we should be able to gain further market shares with innovative products. This will be the main focus of our work in the coming months”, says Michael Kaschke. After R&D positions at IBM and Carl Zeiss, Michael Kaschke PhD has held executive positions in the area of medical technology since 1995. In October 2000, he has been appointed member of the management board of Carl Zeiss AG, among other things concerned with medical technology. He was responsible for the going public of Carl Zeiss Medical Technologies, which led to the foundation of Carl Zeiss Meditec AG. Patrick Kofler Director Investor Relations Phone: +49 3641 220-106 Fax: +49 3641 220-117 E-Mail: investors@meditec.zeiss.com Number: 0145-2008-ENG OP Number of Words: 386 Number of Signs: 2421 |
|